|
|
News Breaks | | | | September 26, 2012 | | 07:32 EDT |  | NBY | NovaBay Pharmaceuticals receives $2.6M from partner Galderma
NovaBay Pharmaceuticals announced that it has received $2.6M from partner Galderma S.A., a global leading pharmaceutical company exclusively focused on dermatology. The payment is associated with the clinical advancement of NovaBay's "non-antibiotic, anti-infective" Aganocide compound NVC-422 as a topical formulation moving to replace traditional antibiotics for the impetigo treatment, a highly contagious skin infection caused by common bacteria such as methicillin-resistant Staphylococcus aureus, or MRSA. | |
|
News For NBY From The Last 14 Days Check below for free stories on NBY the last two weeks. |
|
|
| There are no results for NBY |
|
|
|
|
|
|
